Hua Medicine (HKEX: 2552), a Shanghai-based drug development company focused on developing a global first-in-class oral drug for the treatment of Type 2 diabetes, announced today that the China National Intellectual Property Administration (CNIPA) has issued a patent on a controlled release formulation of dorzagliatin.
Hua Medicine, a China-based drug development company with a focus on developing a global first-in-class oral drug for the treatment of Type 2 diabetes, successfully completed its initial public offering, or IPO, and listing on the Hong Kong Stock Exchange.
Hua Medicine, a leading clinical stage biotechnology company based in Shanghai, announced Wenjie Xu, an experienced sales & marketing veteran in China, joins Hua Medicine as VP, Head of Commercial Strategy and Marketing.
Hua Medicine, a clinical-stage drug development company developing novel therapies for the treatment of Type 2 diabetes, announced the closing of a combined Series D & Series E financing of US$ 117.4 million.
Hua Medicine, a leading clinical stage biotechnology company based in Shanghai, announced that George Lin, a seasoned investment banker in the U.S. and Asia, joined Hua Medicine as EVP and Chief Financial Officer.
Hua Medicine, a leading clinical stage biotech company in Shanghai, announced today positive results in the first-ever successful Phase 2 monotherapy trial of a novel drug class called glucokinase activators (GKA). The company's 4th-generation GKA, HMS5552, targets one of the key enzymes (GK) that act as a 'glucose sensor' and regulates the pathways for carbohydrate metabolism.
Hua Medicine, a leading clinical stage biotech company in Shanghai, announced the successful completion of its Phase II clinical trial for HMS5552, a novel 1st-in-class Glucokinase Activator (GKA) for the treatment of diabetes.
Hua Medicine, a clinical-stage company developing first-in-class and best-in-class therapies for China and the world-wide market, announced the closing of a combined US Dollar- and Chinese Renminbi-denominated investment of approximately $50 million in Series C financing.
Hua Medicine announced today its third successful clinical trial of lead program HMS5552, a novel glucokinase activator (GKA) treatment for Type 2 diabetes (T2DM). This latest Phase 1c trial demonstrated an impressive 1% HbA1c average reduction in patients compared to their baseline blood levels after only 4 weeks of treatment.